Please ensure Javascript is enabled for purposes of website accessibility

Why Guardant Health Stock Jumped Today

By Keith Speights - Mar 4, 2020 at 3:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An overdone sell-off earlier this week combined with overall market gains led to the liquid biopsy stock's big jump.

What happened

Shares of Guardant Health (GH -4.04%) were jumping 11.7% higher as of 3:26 p.m. EST on Wednesday. The liquid biopsy leader didn't report any new developments. However, the major stock market indexes delivered big gains after former Vice President Joe Biden racked up multiple wins in the Democratic primaries on Tuesday, lifting most stocks. Guardant Health likely benefited more than most stocks because the sell-off of its shares on Monday appears to have been overdone.

So what

Growth stocks like Guardant Health tend to have more dramatic price swings when the overall market experiences significant moves. However, the company's prospects shouldn't be impacted all that much regardless of which candidate wins the Democratic nomination for president.

Test tube containing an image of DNA

Image source: Getty Images.

There's a good argument to be made that Guardant Health's shares fell too much on Monday after the company filed a shelf registration statement with the Securities and Exchange Commission (SEC). Although the filing paves the way for Guardant Health to raise more cash in the future through a stock offering, the company shouldn't need any additional money to fund operations anytime soon. Guardant Health's cash position stood at $791.6 million as of Dec. 31, 2019. 

Now what

Guardant Health's business should keep on booming. The company projects that its revenue will grow by around 31% in 2020, driven by sales of its Guardant360 and GuardantOmni liquid biopsy products. This growth could accelerate in the future, though, if Guardant Health gets a green light to market its Lunar-1 and Lunar-2 liquid biopsies for early detection of cancer and monitoring for cancer recurrence.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Guardant Health, Inc. Stock Quote
Guardant Health, Inc.
$40.34 (-4.04%) $-1.70

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.